PXD080173

PXD080173 is an original dataset announced via ProteomeXchange.

Title	Global Proteomics Analysis of S-023-0996 Treatment in Human Breast Cancer Cell line MDA-MB-231
Description	To elucidate the mechanism underlying the anticancer activity of S-023-0996, global proteomic analysis was performed in human breast cancer cells. Mass spectrometry-based proteomic profiling was carried out in MDA-MB-231 cells following treatment with four experimental groups: Tazemetostat (Taz), Gefitinib (Gef), a combination of Tazemetostat and Gefitinib (Taz + Gef), and S-023-0996 (41a), along with a vehicle control (Control). The proteomic profiles of each treatment group were compared with that of the control, and the differential protein expression specific to S-023-0996 was subsequently analysed to elucidate the molecular mechanisms underlying its superior anticancer activity.
HostingRepository	PRIDE
AnnounceDate	2026-09-04
AnnouncementXML	Submission_2026-09-04_01:47:21.203.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Dipak Datta
SpeciesList	scientific name: Homo sapiens (Human); NCBI TaxID: NEWT:9606;
ModificationList	acetylated residue; monohydroxylated residue; iodoacetamide derivatized residue
Instrument	Orbitrap Exploris 240

Revision	Datetime	Status	ChangeLog Entry
0	2026-06-25 07:06:06	ID requested
⏵ 1	2026-09-04 01:47:22	announced

10.1016/j.ymthe.2026.08.034;

Satrusal SR, Banerjee A, Biswas A, Srivastava G, Chatterjee I, Khan MA, Mandal B, Tripathi K, Sinha A, Verma A, Rai P, Akbar M, Kumar S, Chatterjee S, Singh K, Nazir A, Bhatta RS, Panda G, Datta D, Targeting EZH2 and EGFR Therapeutic Vulnerabilities of TNBC with a Single Chemical Entity Confers Preclinical Treatment Advantage. Mol Ther, ():(2026) [pubmed]

submitter keyword: Dual inhibitor, Global proteomics,Breast cancer, EZH2, EGFR, LC-MS/MS

Dr. Dipak Datta
contact affiliation	Chief Scientist, Professor and Head, Cancer Biology Division CSIR-Central Drug Research Institute & AcSIR, LSS-006 Jankipuram Extension, Lucknow 226031, India
contact email	dipak.datta@cdri.res.in
lab head
Dipak Datta
contact affiliation	Chief Scientist, Professor and Head, Cancer Biology Division CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh
contact email	dipak.datta@cdri.res.in
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/09/PXD080173

PRIDE project URI

• PRIDE
  1. PXD080173
     1. Label: PRIDE project
     2. Name: Global Proteomics Analysis of S-023-0996 Treatment in Human Breast Cancer Cell line MDA-MB-231